MiR-17-92 has been suggested to play a major role in the development of mixed-lineage leukemia (MLL)-rearranged leukemias by inhibiting cell differentiation and apoptosis, whereas promoting cell proliferation, through the regulation of relevant target genes [36]. Here, KMT2A is linked to leukemia.